Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy
Drug Design, Development and Therapy · 2023-02 · Volume 17 · 363-367
DOI: 10.2147/dddt.s339349 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2023-02. Verfasst von Nancy A Phillips und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department Obstetrics, Gynecology & Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Hauptthemen laut MEDLINE: Candidiasis, Vulvovaginal, Triterpenes. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department Obstetrics, Gynecology & Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Zitieren
APA
Phillips, N. A., Rocktashel, M., & Merjanian, L. (2023). Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy. Drug Design, Development and Therapy, Volume 17, 363-367. https://doi.org/10.2147/dddt.s339349
Vancouver
Phillips NA, Rocktashel M, Merjanian L. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy. Drug Design, Development and Therapy. 2023;Volume 17:363-367. doi:10.2147/dddt.s339349
BibTeX
@article{Phillips2023,
author = {Phillips, Nancy A and Rocktashel, Maria and Merjanian, Lena},
title = {Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy},
journal = {Drug Design, Development and Therapy},
year = {2023},
volume = {Volume 17},
pages = {363--367},
doi = {10.2147/dddt.s339349}
}
EUVIMED